📊 CNTA Key Takeaways
Investment Thesis
Centessa is a clinical-stage biopharmaceutical company with severe financial distress, burning through $138M in operating cash annually with only $50.8M in cash reserves, providing minimal runway. The company generated negligible revenue ($15M, down 100% YoY) while operating losses exceeded $139M, indicating it is far from commercialization. With negative operating margins of -928% and free cash flow of -$138.4M, the company faces existential solvency risk without immediate capital raises or transformative value creation.
CNTA Strengths
- Strong balance sheet composition with $301.6M stockholders' equity and low debt/equity ratio of 0.36x, reducing bankruptcy risk from leverage
- Excellent current and quick ratios (10.57x) indicating sufficient short-term liquidity to meet immediate obligations
- Early-stage pharmaceutical pipeline positioning with 11 Form 4 insider filings suggesting ongoing management activity
CNTA Risks
- Catastrophic cash burn rate of $138M annually with only $50.8M cash reserves, indicating less than 5 months of runway at current burn rate
- Complete revenue collapse (down 100% YoY) with only $15M recognized, demonstrating failure of commercial efforts or product discontinuation
- Massive operating losses with -928% operating margin and -875% net margin indicating business model is fundamentally broken and unprofitable at scale
- Negative interest coverage ratio of -55x reflects inability to service debt from operations; dependent on cash reserves and capital markets
- Pre-commercial pharmaceutical company facing typical clinical development risk with no approved commercial products generating meaningful revenue
Key Metrics to Watch
- Cash burn rate trend and remaining months of runway before insolvency
- Clinical trial progress and potential FDA approvals that could enable revenue generation
- Capital raise announcements and terms that would dilute existing shareholders
- Operating cash flow trajectory and any improvements in cash efficiency
CNTA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.57x current ratio provides a solid financial cushion.
CNTA Profitability Ratios
CNTA vs Healthcare Sector
How Centessa Pharmaceuticals plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CNTA Balance Sheet & Liquidity
CNTA 5-Year Financial Trend
5-Year Trend Summary: Centessa Pharmaceuticals plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.57 indicates the company is currently unprofitable.
CNTA Growth Metrics (YoY)
CNTA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$42.6M | $-0.37 |
| Q2 2025 | N/A | -$43.8M | $-0.38 |
| Q1 2025 | N/A | -$26.1M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CNTA Capital Allocation
CNTA SEC Filings
Access official SEC EDGAR filings for Centessa Pharmaceuticals plc (CIK: 0001847903)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNTA
What is the AI rating for CNTA?
Centessa Pharmaceuticals plc (CNTA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNTA's key strengths?
Strong balance sheet composition with $301.6M stockholders' equity and low debt/equity ratio of 0.36x, reducing bankruptcy risk from leverage. Excellent current and quick ratios (10.57x) indicating sufficient short-term liquidity to meet immediate obligations.
What are the risks of investing in CNTA?
Catastrophic cash burn rate of $138M annually with only $50.8M cash reserves, indicating less than 5 months of runway at current burn rate. Complete revenue collapse (down 100% YoY) with only $15M recognized, demonstrating failure of commercial efforts or product discontinuation.
What is CNTA's revenue and growth?
Centessa Pharmaceuticals plc reported revenue of $15.0M.
Does CNTA pay dividends?
Centessa Pharmaceuticals plc does not currently pay dividends.
Where can I find CNTA SEC filings?
Official SEC filings for Centessa Pharmaceuticals plc (CIK: 0001847903) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNTA's EPS?
Centessa Pharmaceuticals plc has a diluted EPS of $-0.98.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.